文献速递血脂与心血管预防

JUPITER试验:胆固醇流出能力、HDL颗粒数与心血管事件

Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
PubMed 文献 · Circulation · 2017-04-27

在JUPITER试验的巢式病例对照研究中,基线HDL颗粒数与心血管事件风险呈负相关,而胆固醇流出能力无显著关联;瑞舒伐他汀治疗12个月未改变胆固醇流出能力,但升高HDL颗粒数,且用药后胆固醇流出能力与事件负相关,HDL颗粒数始终是最强预测指标。

要点

  • 基线HDL颗粒数每增加1个标准差,心血管事件风险降低(OR 0.69)。
  • 基线胆固醇流出能力与心血管事件无显著关联(OR 0.89,P=0.28)。
  • 瑞舒伐他汀20mg/日治疗12个月未改变胆固醇流出能力,但升高HDL颗粒数。

核心结论

  • 在JUPITER试验中,胆固醇流出能力仅在瑞舒伐他汀治疗后的个体中与心血管事件相关,基线时无显著关联;基线和用药后分析中,HDL颗粒数均为4种HDL相关生物标志物中最强的心血管事件负向预测指标和残余风险标志物。

研究设计与样本

  • JUPITER试验(比较瑞舒伐他汀与安慰剂的随机一级预防试验)的巢式病例对照研究,纳入314例心血管疾病事件病例并与年龄性别匹配的对照比较,评估基线及12个月时HDL相关指标。

主要发现

  • 基线HDL颗粒数与心血管事件呈负相关(每增加1个标准差,校正OR 0.69;95%CI 0.56-0.86;P<0.001),而基线胆固醇流出能力(OR 0.89;95%CI 0.72-1.10;P=0.28)、HDL胆固醇(OR 0.82;95%CI 0.66-1.02;P=0.08)、载脂蛋白A-I(OR 0.83;95%CI 0.67-1.03;P=0.08)无显著关联。
  • 瑞舒伐他汀20mg/日治疗12个月未改变胆固醇流出能力(平均百分比变化-1.5%,95%CI -13.3至+10.2;P=0.80),但升高HDL胆固醇(+7.7%)、载脂蛋白A-I(+4.3%)和HDL颗粒数(+5.2%)。
  • 用药后胆固醇流出能力与心血管事件负相关(每增加1个标准差,OR 0.62;95%CI 0.42-0.92;P=0.02),HDL颗粒数仍为最强预测指标(OR 0.51;95%CI 0.33-0.77;P<0.001)。

关键数值与推荐

  • 基线HDL颗粒数每增加1个标准差,心血管事件校正OR 0.69(95%CI 0.56-0.86;P<0.001)。
  • 基线胆固醇流出能力每增加1个标准差,OR 0.89(95%CI 0.72-1.10;P=0.28),无显著关联。
  • 瑞舒伐他汀20mg/日治疗12个月,胆固醇流出能力平均百分比变化-1.5%(95%CI -13.3至+10.2;P=0.80),HDL颗粒数升高5.2%。
  • 用药后胆固醇流出能力每增加1个标准差,OR 0.62(95%CI 0.42-0.92;P=0.02);HDL颗粒数OR 0.51(95%CI 0.33-0.77;P<0.001)。

临床怎么用

  • 在服用强效他汀且低密度脂蛋白胆固醇较低的人群中,HDL颗粒数可能作为残余风险的生物标志物,而胆固醇流出能力的预测价值依赖于他汀治疗状态。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number. However, no studies have directly compared these metrics in a contemporary population that includes potent statin therapy and low low-density lipoprotein cholesterol. METHODS: HDL cholesterol levels, apolipoprotein A-I, cholesterol efflux capacity, and HDL particle number were assessed at baseline and 12 months in a nested case-control study of the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), a randomized primary prevention trial that compared rosuvastatin treatment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reactive protein levels. In total, 314 cases of incident cardiovascular disease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or cardiovascular death) were compared to age- and gender-matched controls. Conditional logistic regression models adjusting for risk factors evaluated associations between HDL-related biomarkers and incident CVD. RESULTS: Cholesterol efflux capacity was moderately correlated with HDL cholesterol, apolipoprotein A-I, and HDL particle number (Spearman r= 0.39, 0.48, and 0.39 respectively; P<0.001). Baseline HDL particle number was inversely associated with incident CVD (adjusted odds ratio per SD increment [OR/SD], 0.69; 95% confidence interval [CI], 0.56-0.86; P<0.001), whereas no significant association was found for baseline cholesterol efflux capacity (OR/SD, 0.89; 95% CI, 0.72-1.10; P=0.28), HDL cholesterol (OR/SD, 0.82; 95% CI, 0.66-1.02; P=0.08), or apolipoprotein A-I (OR/SD, 0.83; 95% CI, 0.67-1.03; P=0.08). Twelve months of rosuvastatin (20 mg/day) did not change cholesterol efflux capacity (average percentage change -1.5%, 95% CI, -13.3 to +10.2; P=0.80), but increased HDL cholesterol (+7.7%), apolipoprotein A-I (+4.3%), and HDL particle number (+5.2%). On-statin cholesterol efflux capacity was inversely associated with incident CVD (OR/SD, 0.62; 95% CI, 0.42-0.92; P=0.02), although HDL particle number again emerged as the strongest predictor (OR/SD, 0.51; 95% CI, 0.33-0.77; P<0.001). CONCLUSIONS: In JUPITER, cholesterol efflux capacity was associated with incident CVD in individuals on potent statin therapy but not at baseline. For both baseline and on-statin analyses, HDL particle number was the strongest of 4 HDL-related biomarkers as an inverse predictor of incident events and biomarker of residual risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Khera AV, Demler OV, Adelman SJ, et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017. PMID: 28450350. doi:10.1161/CIRCULATIONAHA.116.025678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。